Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2012

View Archived Issues

Novel antimitotic compounds created in joint venture

ProINS-Tf fusion protein displays hypoglycemic activity

Vivalis discloses novel agents for hepatitis C virus infection

An anti-M1 prime monoclonal antibody shows promising results in allergic rhinitis and asthma

Researchers at the University of California divulge new SEH inhibitors

Novel ROCK-II inhibitors prepared at Boehringer Ingelheim

New proton pump inhibitor shows promise in Japanese patients with GERD

Combination of Ad-rhE and chemotherapy proves beneficial in cancer patients

Oncolytic viral therapy shows potential as treatment for superficial tumors

Enrollment completed in phase II study of NP-2 enkephalin in cancer pain

Phase I trial opens enrollment for GeoVax Labs' HIV vaccine

AVEO begins phase I AV-203 study in advanced solid tumors

Novel pegylated interferon alpha variant conjugates generated in China

Phase III CompleoTRT trial nearing full enrollment

Seattle Genetics' Adcetris NDS accepted for review by Health Canada

Pfizer presents new ACC inhibitors

Label update approved for Tysabri to include anti-JC virus antibody status

Korean scientists present novel HIF-1 inhibitors

Preliminary phase I results show IW-001 to be well tolerated

XDx and LabCorp enter collaboration for SLE diagnostic

EMA acceptance of Takeda's alogliptin MAA triggers milestone payment for Furiex

FDA advisory committee votes against Xarelto use in new ACS indication

Preliminary phase IIb results display encouraging responses to Celldex' CDX-011

EMA validates Gilead's MAA for boosting agent cobicistat

MediciNova reports preliminary results for MN-221 in asthma exacerbations

Immune Pharmaceuticals and Yeda partner to develop anticancer therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.